canyon landscape

multiple sclerosis

NeuroNEXT NN111

A phase-2B, double-blind, randomized controlled trial to evaluate the activity and safety of inebilizumab in anti-NMDA receptor encephalitis and assess markers of disease. Purpose There are currently no...

TREAT-MS

FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in...